Search results
26 sie 2021 · Similarly, Ayhan et al. observed that median overall survival was 3.8 years without ascites, 2.3 years with <5000 mL of ascites, and 1.5 years in those with >5000 mL. The ascitic fluid volume also correlated with the number of tumor metastasis.
The median survival following diagnosis of ascites was 5.7 months. Ovarian cancer favoured longer survival while low serum albumin, low serum protein and liver metastases adversely affected survival. The independent prognostic factors for survival were cancer type, liver metastases and serum albumin.
26 sie 2021 · Despite decades of evidence showing that the accumulation of peritoneal fluid portends the poorest outcomes for cancer patients, the role of malignant ascites in promoting metastasis and therapy resistance remains poorly understood. This review summarizes the current understanding of malignant ascites, with a focus on ovarian cancer.
8 maj 2020 · Ascites is present in more than one third of ovarian cancer patients at initial diagnosis and in almost all cases of relapse. 3, 8, 9 The greater the volume and frequency with which ascites...
Malignant ascites is one of the most common sequela of epithelial ovarian cancer. It causes significant symptoms and can have a detrimental impact on patient quality of life, especially in women with recurrent ovarian cancer.
20 lis 2021 · Statement: Patients with massive ascites with PD often have a predicted life expectancy of PS3 on a weekly basis, and abdominal bloating and repeated abdominal punctures can be avoided by performing abdominal-venous shunt (AVS, Denver's shunt).
28 maj 2021 · Background: Malignant ascites (MA) is associated with progressive deterioration in quality of life and poor prognosis of patients with cancer. Paracentesis is among the most widely utilised treatments for MA.
